Free Trial

BrainsWay Q4 2022 Earnings Report

BrainsWay logo
$9.24 +0.28 (+3.13%)
(As of 12/20/2024 05:15 PM ET)

BrainsWay EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.12
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

BrainsWay Revenue Results

Actual Revenue
$6.03 million
Expected Revenue
$6.10 million
Beat/Miss
Missed by -$70.00 thousand
YoY Revenue Growth
N/A

BrainsWay Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

BrainsWay Earnings Headlines

Brainsway reports independent pilot data on Deep TMS technology for AUD
AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
Brainsway announces publication on pain reduction with Deep TMS therapy
BrainsWay: Cash Flow Doubts Weigh On The Stock
See More BrainsWay Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BrainsWay? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BrainsWay and other key companies, straight to your email.

About BrainsWay

BrainsWay (NASDAQ:BWAY) develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

View BrainsWay Profile

More Earnings Resources from MarketBeat

Upcoming Earnings